North American Palladium Ltd (USA) (NYSEMKT:PAL) announced an update on its proposed second tranche of the earlier announced public offering involving 7.5% convertible unsecured subordinate debentures. The update includes an amendment to the policy and expected closing scheduled. It also announced primary palladium production results for the first quarter of 2014. North American Palladium Ltd (USA) (NYSEMKT:PAL) shares after opening at $0.32 moved to $0.32 on last trade day and at the end of the day closed at $0.303. Company price to sales ratio in past twelve months was calculated as 0.58 and price to cash ratio as 8.96. North American Palladium Ltd (USA) (NYSEMKT:PAL) showed a negative weekly performance of -37.50%.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced results of two new preclinical studies evaluating novel combinations of TH-302, its investigational hypoxia-targeted drug, with immunotherapy, antiangiogenic therapy. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares fell -6.47% in last trading session and ended the day on $4.05. THLD return on equity ratio is recorded as 129.10% and its return on assets is -26.80%. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) yearly performance is -12.72%.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), announced a letter agreement with Pfizer Inc. providing for the termination of Pfizer’s license to Acura’s AVERSION® Technology and the return to Acura of the FDA approved Oxecta® (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares moved down -2.27% in last trading session and was closed at $1.29 while trading in range of $1.17 – $1.33 – Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) year to date (YTD) performance is -22.75%.
Curis, Inc. (NASDAQ:CRIS) announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergybetween Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Curis, Inc. (NASDAQ:CRIS) weekly performance is -10.57%. On last trading day company shares ended up $2.37. Curis, Inc. (NASDAQ:CRIS) distance from 50-day simple moving average (SMA50) is -20.08%. Analysts mean target price for the company is $5.72.